Barry Buckland

Synglyco, Inc. develops novel vaccines using synthetic carbohydrates. The firm's cutting edge technology enables the rapid, milligram to kilogram production of synthetic carbohydrates for use in drug discovery and industrial applications. Its proprietary platform generates significant quantities of chemically pure, complex carbohydrates through automated and manual chemical synthesis. The company was founded by Peter H. Seeberger, Carmichael S. Roberts Jr. Obadiah J. Plante and Louis Schofield on June 18, 2001 and is headquartered in New York, NY.

Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life.

Enumeral Biomedical Corp. develops monoclonal antibodies for diagnosis and treatment of infectious, autoimmune and inflammatory diseases. Its proprietary micro engraving technology creates spatially-registered, high-density bio-chip microarrays of the secreted products of single human cells derived from patient samples to provide rapid and simultaneous analysis of antibody affinity and specificity as well as cytokine profiles and T-cell functionality. The company was founded in 2009 by J. Christopher Love, Emanuele Ostuni and Barry Buckland and is headquartered in New York, NY.

Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands.

Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA.

Engineering Conferences International, Inc. organizes engineering conferences program. The private company is based in New York.

The National Institute for Innovation in Manufacturing Biopharmaceuticals operates as a consortium of small, medium, and large biopharmaceutical companies. The private company is based in Newark.